ABL
Clément Canu is currently working as a Technicien contrôle qualité at ABL Europe since January 2020. Prior to this, Clément was an Apprenti at IGBMC from September 2018 to September 2019, and completed a Stage étudiant at EA 3072 and EA 7296 in 2018 and 2017 respectively. Clément holds a Licence professionnelle in Biotechnologie from Université de Haute-Alsace Mulhouse-Colmar, a BTS in Biotechnologies from Lycée Jean Rostand Strasbourg, and a Baccalauréat Scientifique from Lycée Saint André Colmar.
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.